Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.

Nicla La Verde, Anna Moretti, Gabriella Farina, Maria Chiara Dazzani, Teresa Gamucci, Karen Borgonovo, Mario Botta, Nello Salesi, Monica Zuradelli, Ida Pavese, Elena Barbieri, Elisabetta Cretella, Tiziana Saladino, Paola Varese, Elena Silvia Traverso, Gianfranco Addamo, Mariangela Ciccarese, Anna Iolanda Rispoli, Arianna Pellegrino, Lucia MentucciaSerena Girelli, Sheila Piva, Massimo Di Maio

Research output: Contribution to journalArticle

Abstract

This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.

Original languageEnglish
Pages (from-to)1841-1848
Number of pages8
JournalFuture Oncology
Volume9
Issue number12
Publication statusPublished - Dec 2013

Fingerprint

eribulin
Skin Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Skin
Therapeutics
Disease-Free Survival
Observational Studies
Neoplasms
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

La Verde, N., Moretti, A., Farina, G., Dazzani, M. C., Gamucci, T., Borgonovo, K., ... Di Maio, M. (2013). Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncology, 9(12), 1841-1848.

Eribulin in cutaneous breast cancer metastasis treatment : clinical activity and symptom control. / La Verde, Nicla; Moretti, Anna; Farina, Gabriella; Dazzani, Maria Chiara; Gamucci, Teresa; Borgonovo, Karen; Botta, Mario; Salesi, Nello; Zuradelli, Monica; Pavese, Ida; Barbieri, Elena; Cretella, Elisabetta; Saladino, Tiziana; Varese, Paola; Traverso, Elena Silvia; Addamo, Gianfranco; Ciccarese, Mariangela; Rispoli, Anna Iolanda; Pellegrino, Arianna; Mentuccia, Lucia; Girelli, Serena; Piva, Sheila; Di Maio, Massimo.

In: Future Oncology, Vol. 9, No. 12, 12.2013, p. 1841-1848.

Research output: Contribution to journalArticle

La Verde, N, Moretti, A, Farina, G, Dazzani, MC, Gamucci, T, Borgonovo, K, Botta, M, Salesi, N, Zuradelli, M, Pavese, I, Barbieri, E, Cretella, E, Saladino, T, Varese, P, Traverso, ES, Addamo, G, Ciccarese, M, Rispoli, AI, Pellegrino, A, Mentuccia, L, Girelli, S, Piva, S & Di Maio, M 2013, 'Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.', Future Oncology, vol. 9, no. 12, pp. 1841-1848.
La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K et al. Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncology. 2013 Dec;9(12):1841-1848.
La Verde, Nicla ; Moretti, Anna ; Farina, Gabriella ; Dazzani, Maria Chiara ; Gamucci, Teresa ; Borgonovo, Karen ; Botta, Mario ; Salesi, Nello ; Zuradelli, Monica ; Pavese, Ida ; Barbieri, Elena ; Cretella, Elisabetta ; Saladino, Tiziana ; Varese, Paola ; Traverso, Elena Silvia ; Addamo, Gianfranco ; Ciccarese, Mariangela ; Rispoli, Anna Iolanda ; Pellegrino, Arianna ; Mentuccia, Lucia ; Girelli, Serena ; Piva, Sheila ; Di Maio, Massimo. / Eribulin in cutaneous breast cancer metastasis treatment : clinical activity and symptom control. In: Future Oncology. 2013 ; Vol. 9, No. 12. pp. 1841-1848.
@article{cb49383606bc49e3a7f07148758d073e,
title = "Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.",
abstract = "This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43{\%} of patients exhibited a partial response, 35{\%} stable disease and 22{\%} progressive disease. Regarding only the skin response, 26{\%} obtained a complete response, 22{\%} a partial response, 39{\%} stable disease and 13{\%} progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.",
author = "{La Verde}, Nicla and Anna Moretti and Gabriella Farina and Dazzani, {Maria Chiara} and Teresa Gamucci and Karen Borgonovo and Mario Botta and Nello Salesi and Monica Zuradelli and Ida Pavese and Elena Barbieri and Elisabetta Cretella and Tiziana Saladino and Paola Varese and Traverso, {Elena Silvia} and Gianfranco Addamo and Mariangela Ciccarese and Rispoli, {Anna Iolanda} and Arianna Pellegrino and Lucia Mentuccia and Serena Girelli and Sheila Piva and {Di Maio}, Massimo",
year = "2013",
month = "12",
language = "English",
volume = "9",
pages = "1841--1848",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Eribulin in cutaneous breast cancer metastasis treatment

T2 - clinical activity and symptom control.

AU - La Verde, Nicla

AU - Moretti, Anna

AU - Farina, Gabriella

AU - Dazzani, Maria Chiara

AU - Gamucci, Teresa

AU - Borgonovo, Karen

AU - Botta, Mario

AU - Salesi, Nello

AU - Zuradelli, Monica

AU - Pavese, Ida

AU - Barbieri, Elena

AU - Cretella, Elisabetta

AU - Saladino, Tiziana

AU - Varese, Paola

AU - Traverso, Elena Silvia

AU - Addamo, Gianfranco

AU - Ciccarese, Mariangela

AU - Rispoli, Anna Iolanda

AU - Pellegrino, Arianna

AU - Mentuccia, Lucia

AU - Girelli, Serena

AU - Piva, Sheila

AU - Di Maio, Massimo

PY - 2013/12

Y1 - 2013/12

N2 - This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.

AB - This observational study evaluated the behavior and outcome of cutaneous breast cancer metastasis treated with eribulin. From November 2012 to January 2013, oncologists completed a database with patient, tumor and treatment characteristics from 14 Italian cancer centers. Skin lesions were assessed by Response Evaluation Criteria In Solid Tumors and cutaneous symptoms by present/absent criteria. A total of 23 metastatic breast cancer patients with skin metastasis who were treated with eribulin were analyzed. After treatment, 43% of patients exhibited a partial response, 35% stable disease and 22% progressive disease. Regarding only the skin response, 26% obtained a complete response, 22% a partial response, 39% stable disease and 13% progressive disease. We found an improvement in symptoms, infiltration and ulceration. With a median follow-up of 6 months, median progression-free survival was 4.3 months and median overall survival was 9.1 months. The response rate of skin metastasis to eribulin treatment was coherent with systemic responses. The good clinical response in most patients reflected symptom improvement.

UR - http://www.scopus.com/inward/record.url?scp=84903686115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903686115&partnerID=8YFLogxK

M3 - Article

C2 - 24295414

AN - SCOPUS:84903686115

VL - 9

SP - 1841

EP - 1848

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12

ER -